Treating patients with resectable esophagogastric cancer with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) may be superior to epirubicin, cisplatin, with fluorouracil or capecitabine (ECF/ECX), according to results from a trial presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Spain.1
http://www.cancertherapyadvisor.com/esmo-2017/esophageal-cancer-standard-flot-combination-therapy/article/687631/
FLOT Combination Therapy May Be a New Standard for Esophageal Cancer